Curium to Acquire Lantheus in $8 Billion Radiopharmaceutical Deal
Question
Curium to Acquire Lantheus in $8 Billion Radiopharmaceutical Deal
Direct answer
The $8 billion acquisition of Lantheus by Curium underscores the intensifying interest in radiopharmaceuticals. By combining diagnostics with therapeutics, the new entity aims to dominate the 'theranostics' market. The inclusion of CVRs suggests that while Curium is bullish, it is hedging against specific regulatory or commercial milestones for Lantheus's pipeline.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-03
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Curium to Acquire Lantheus in $8 Billion Radiopharmaceutical Deal”, revision 1, evidence through 2026-08-03. https://marketontology.com/market-events/2026-08-03/curium-to-acquire-lantheus-in-8-billion-radiopharmaceutical-deal-66b99b
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.